Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting indolent non-Hodgkin lymphoma.
Leslie LA, Skarbnik AP, Bejot C, Stives S, Feldman TA, Goy AH. Leslie LA, et al. Among authors: goy ah. Expert Rev Hematol. 2017 Apr;10(4):299-313. doi: 10.1080/17474086.2017.1303374. Epub 2017 Mar 15. Expert Rev Hematol. 2017. PMID: 28277849 Review.
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Goy A, et al. J Clin Oncol. 2005 Feb 1;23(4):667-75. doi: 10.1200/JCO.2005.03.108. Epub 2004 Dec 21. J Clin Oncol. 2005. PMID: 15613697 Clinical Trial.
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Romaguera JE, et al. Br J Haematol. 2010 Oct;151(1):47-53. doi: 10.1111/j.1365-2141.2010.08315.x. Epub 2010 Aug 5. Br J Haematol. 2010. PMID: 20735402 Free article. Clinical Trial.
Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.
Mato AR, Svoboda J, Feldman T, Zielonka T, Agress H, Panush D, Miller M, Toth P, Lizotte PM, Nasta S, Goldberg S, Chong E, Schuster S, Pecora AL, Goy A. Mato AR, et al. Cancer. 2012 Jul 15;118(14):3565-70. doi: 10.1002/cncr.26731. Epub 2011 Dec 16. Cancer. 2012. PMID: 22180256 Free article.
225 results